November 7, 2024
Headlines

EyePoint’s Investigational Drug Shows Early And Sustained Improvement Than Regeneron’s Eylea For Diabetes-Associated Vision Loss

01 mins

EyePoint Pharmaceuticals’ shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News